Shanghai Sanyou Medical Co., Ltd acquires its controlling subsidiary at a 4 times premium, with the necessity of the Trade and performance commitments being key points of inquiry.
① Shanghai Sanyou Medical Co., Ltd intends to acquire the remaining shares of its subsidiary, Shuimu Tianpeng. An assessment indicates that Shuimu Tianpeng's value has increased by 0.693 billion yuan, with a value increase rate of 406.21%. ② Shanghai Sanyou Medical Co., Ltd stated that the acquisition is beneficial for enhancing the company's overall profitability. Prior to the acquisition, Shanghai Sanyou Medical Co., Ltd had consistently faced declining performance.
After investing 1.5 billion over three years to build a Global research and development headquarters, can Zhejiang Orient Gene Biotech win this "turnaround battle"?
① Zhejiang Orient Gene Biotech spent 0.29 billion yuan to acquire land in Zhangjiang, planning to build a global digital research and development innovation headquarters project with a total investment of 1.5 billion yuan, expected to achieve annual sales revenue of 1.5 billion yuan upon reaching production capacity. ② After the demand for nucleic acid testing declined, Zhejiang Orient Gene Biotech encountered a performance "slump", remaining in a net loss of over 260 million yuan until the first three quarters of 2024.
Cancellation of high-tech enterprise qualification may require shanghai microport endovascular medtech(group)co.,ltd. to pay an additional 70 million in taxes.
shanghai microport endovascular medtech(group)co.,ltd. needs to pay up to 70 million yuan in back taxes due to the cancellation of its high-tech enterprise qualification certification, which is expected to account for more than 10% of the net income in the most recent fiscal year. shanghai microport endovascular medtech(group)co.,ltd. stated that it is currently communicating with relevant units regarding this matter; In addition, shanghai microport endovascular medtech(group)co.,ltd. previously revealed that without considering the impact of non-operating risk factors, the projected growth of the attributable net income in 2024 is around 0-10%.
Former Alibaba CEO Wei Zhe joins sansure biotech inc. Latest response: will not involve business related to mergers and acquisitions by Sanshong.
①Wei Zhe expressed that the reason for joining sansure biotech inc. was to deeply empower the medical industry and gain in-depth understanding of the medical industry; ②He recently posted on his Moments saying that his ideas are highly consistent with sansure biotech inc. and the company's director and general manager, and he will deeply cultivate the sinking medical system and layout the blueprint for going global; ③At the end of last year, Wei Zhe and his founded Jia Yu Capital began to get involved in the medical health field, and announced the establishment of Jia Yu-Ziniu Medical Fund with Ziniu Fund.
Autobio diagnostics: The molecular sector is experiencing rapid growth, and disputes with the secondary subsidiary may be resolved soon | Direct coverage of the earnings conference.
① The secretary of the board of directors of autobio diagnostics stated at the earnings conference that the significant increase in research and development expenses led to a decline in the net income attributable to the parent company in Q3; ② The chairman of autobio diagnostics, Miao Yongjun, told investors that the molecular sector is expected to maintain a high growth rate, while the microbiology sector will have a steady growth of 15%-20% each year.
Zhende Medical: The US tariff policy has no impact on the company yet, and the Mexican production base may be completed next year | Direct hit on earnings conference
①Zhende Medical's chairman Lu Jianguo introduced at the earnings conference that the construction of the new production base in Mexico is expected to be completed next year; ② Zhende Medical explained the company's Q3 operation situation, with further decrease in revenue from isolation protective equipment.